Investigation of the Effects of Online Education Application on Gynecological Cancer Patients Receiving Chemotherapy

August 24, 2024 updated by: yşegül Beyazpınar KAVAKLIOĞLU, Celal Bayar University

Investigation of the Effect of Online Nursing Education Given to Patients Diagnosed With Gynecological Cancer and Receiving Chemotherapy on Symptoms, Quality of Life and Patient Satisfaction

The aim of the study was to examine the effect of online nursing education given to women diagnosed with gynecological cancer and receiving chemotherapy. It was conducted as a randomized controlled experimental study. The study examined the effect of online nursing education given to patients in the intervention group diagnosed with gynecological cancer and receiving chemotherapy on symptoms, quality of life and patient satisfaction. The control group received routine nursing care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study examined the effect of online nursing education given to women diagnosed with gynecological cancer and receiving chemotherapy. This randomized controlled experimental study was conducted in a public hospital in Balıkesir province between December 1, 2021 and June 1, 2024. The study sample consisted of 90 women (intervention=45, control=45). Online nursing education was given to women in the intervention group receiving chemotherapy. Patients in the control group received routine nursing care. The study used the women's descriptive characteristics questionnaire, disease and treatment questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Nightingale Symptom Assessment Scale, nurse follow-up form and patient satisfaction questionnaire. Data were collected during three chemotherapy cycles in four phases.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Manisa, Turkey, 45010
        • CelalBayarU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who are diagnosed with gynecological cancer and who have started chemotherapy treatment for the first time in the hospital,

having gynecological cancer

receiving chemotherapy

Speak Turkish, have no communication problems,

Accept voluntarily to participate in the study,

Patients who are 18 years of age or older

Exclusion Criteria:

  • Illiterate Patients who do not have a smart phone or computer Patients who receive radiotherapy together with chemotherapy Patients who do not know they have been diagnosed with cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: intervention group
Patients in the intervention group will receive online nursing education and their quality of life and symptom complaints will be monitored by the nurse who provides education during three cycles of chemotherapy. At the end of the third cycle, patients' satisfaction with this education will be determined.
Other: Chemotherapy symptom Management Online Education

Randomization was achieved and data collection began. Patients were given the "Chemotherapy Symptom Management Education Booklet" and were informed that they would be contacted by phone.

In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.

In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated.

Other Names:
  • Chemotherapy symptom Management
  • nursing online education
No Intervention: control group
Patients in the control group will receive routine nursing care. Patients in the control group will be monitored for quality of life and symptom complaints during three cycles of chemotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
EORT QLQ-C30
Time Frame: three monhts
EORT QLQ-C30: It consists of three main dimensions and 30 questions, namely general well-being, functional difficulties and symptom control.
three monhts
Nightingale symptom assessment scale
Time Frame: three monhts
Nightingale symptom assessment scale: This scale, consisting of 38 items, has three sub-dimensions, namely physical, social and psychological well-being.
three monhts

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire,
Time Frame: three monhts
EORT QLQ-C30: It consists of three main dimensions and 30 questions: general well-being, functional difficulties and symptom control. İThe first 28 questions are Likert-type. The other two questions are evaluated as 1: very bad and 7: excellent. Each subscale of the scale is scored between 0-100. High scores from the sub-dimension and general quality of life indicate that the quality of life is high, and high scores from the symptom scale indicate that the symptoms experienced are at a high level.
three monhts
Nightingale Symptom Assessment Scale
Time Frame: three months
Nightingale symptom assessment scale: This scale, consisting of 38 items, has three sub-dimensions: physical, social and psychological well-being. This is a Likert-type scale. The total sub-dimension score is calculated by adding the item scores in each sub-dimension and dividing by the number of items. 0-4 points are taken in each subscale of the scale. A high score indicates that the level of being affected by problems caused by the disease/treatment is high.
three months
patient satisfaction
Time Frame: one months
score average is taken.
one months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Celal Bayar University

Investigators

  • Principal Investigator: ayşegül beyazpınar kavaklıoğlu, student, Celal Bayar University
  • Study Director: emre yanıkkerem, prof.dr., Celal Bayar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2021

Primary Completion (Actual)

January 1, 2023

Study Completion (Actual)

June 1, 2024

Study Registration Dates

First Submitted

August 21, 2024

First Submitted That Met QC Criteria

August 24, 2024

First Posted (Actual)

August 27, 2024

Study Record Updates

Last Update Posted (Actual)

August 27, 2024

Last Update Submitted That Met QC Criteria

August 24, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CelalBayarU-LEE-ABK-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynecological Cancer

Clinical Trials on Chemotherapy symptom Management Online Education

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe